| |||
|
ÌÅÄËÀÉÍ.ÐÓ
|
|||
|
Êëèíè÷åñêàÿ ìåäèöèíà » Õèðóðãèÿ • Îíêîëîãèÿ, ëó÷åâàÿ òåðàïèÿ
Òîì: 12 Ñòàòüÿ: « 33 » Ñòðàíèöû:. 386-409 Îïóáëèêîâàíà â æóðíàëå: ìàé 2011 ã. English version 
Òåðàïèÿ ëèìôîìû Õîäæêèíà ó äåòåé è ïîäðîñòêîâ (îáçîð ëèòåðàòóðû)ÔÃÓ «ÍÈÈ îíêîëîãèè èì. Í.Í.Ïåòðîâà» Ìèíçäðàâñîöðàçâèòèÿ Ðîññèè
Ñ-Ïåòåðáóðã
Ðåçþìå
Îáñóæäåíû îñíîâíûå ýòàïû ðàçâèòèÿ ïðåäñòàâëåíèé î ëå÷åáíîé òàêòèêå ëèìôîìû Õîäæêèíà - îò ìåñòíîé ïàëëèàòèâíîé ëó÷åâîé òåðàïèè äî êîìáèíèðîâàííîãî õèìèîëó÷åâîãî ëå÷åíèÿ. Ïðåäñòàâëåíû îòäàëåííûå ðåçóëüòàòû ðàçëè÷íûõ âàðèàíòîâ òåðàïèè. Êëþ÷åâûå ñëîâà äåòè, ïîäðîñòêè, ëèìôîìà Õîäæêèíà, òåðàïèÿ. (ñòàòüÿ â ôîðìàòå PDF. Äëÿ ïðîñìîòðà íåîáõîäèì Adobe Acrobat Reader)  îòêðûòü ñòàòüþ â íîâîì îêíå
Ñïèñîê ëèòåðàòóðû 1. Êîëûãèí Á.À, Êîáèêîâ Ñ.Õ. Ëèìôîãðàíóëåìàòîç ó äåòåé è ïîäðîñòêîâ / ÑÏá.: Ãèïïîêðàò, 2008. – 264 ñ. 2. Anderson H., Deakin D.-P., Wagstaff Y. et al. A randomized study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin’s disease PS IAIIB: a report from the Manchester Lymphoma Group // Br. J. Cancer. – 1984. – No. 6. – P. 695-702. 3. Atra A., Higgs E., Capra M. et al. ChlVPP chemotherapy in children with stage IV Hodgkin’s disease: results of the UKCCSG HD 8201 and HD 9201 studies // Br. J. Haematol. – 2002. – Vol. 119. – No. 3. – P. 647-651. 4. Baez F., Ocampo E. Treatment of childhood Hodgkin’s disease with COPP-ABV (hybrid) without radiotherapy in Nicaragua // Ann. Oncol. – 1997. – Vol. 8. – No. 3. – P. 247-250. 5. Baker M.C. and Mann W.N. Hodgkin’s disease: a study of sixty-five cases // Guy’s Hosp. Rep. – 1939. – Vol. 89. – P. 83-107. 6. Berkson J. and Gage P. Survival cures for cancer patients following treatment // J. Am. Stat. Assoc. – 1952. – Vol. 47. – P. 501-515. 7. Boiron M., Teillet F., Bernard J. et al. A reappraisal of clinical and biological signs in staging of Hodgkin’s disease // Cancer Res. – 1971. – Vol. 31. – P. 1723-1729. 8. Bonadonna G., Zucali R., Monfardini S. et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP // Cancer. – 1975. – Vol. 36. – P. 252-259. 9. Canellos G.P., Anderson J.R., Propert K.J. et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with AVBD // N. Engl. J. Med. – 1992. – Vol. 327. – P. 1478-1484. 10. Carde P. The chemotherapy/radiation balance in advanced Hodgkin’s lymphoma: overweight which side? // J. Clin. Oncol. – 2005. – Vol. 23. – No. 36. – P. 9058-9062. 11. De Vita V., Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin’s disease [abstract] // Proc.Am.Assoc.Cancer Res. - 1967. – V.8. – P.13. 12. De Vita V., Serpick A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin’s disease // Ann. Intern. Med. – 1970. – Vol. 73. – P. 881-895. 13. Diehl V., Franklin J., Pfreundschuh M. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease // N. Engl. J. Med. – 2003. – Vol. 348. – P. 2386-2395. 14. Donaldson S.S. Pediatric Hodgkin’s disease – up, up, and beyong // Int. J. Radiat. Oncol. Biol. Phys. – 2002. – Vol. 54. – P. 1-8. 15. Donaldson S.S., Link M.P. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin’s disease // J. Clin. Oncol. – 1987. - Vol. 5. – No. 5. – P. 742-749. 16. Dorffel W., Luders H., Ruhl U. et al. Preliminary results of the multicenter trial GPON-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook // Clin. Pediatr. – 2003. – Vol. 215. – P. 139-145. 17. Duggan D.B., Petroni G.R., Johnson J.L. et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an Intergroup Trial // J. Clin. Oncol. – 2003. – Vol. 21. – No. 4. – P. 607-614. 18. Ekert H., Toogood I. High incidence of treatment failure with vincristine, etoposide, epirubicin, and prednisolone chemotherapy with successful salvage in childhood Hodgkin disease // Med. Pediatr. Oncol. – 1999. – Vol. 32. – No. 4. – P. 255-258. 19. Friedmann A.M., Hudson M.M., Weinstein H.J. et al. Treatment of unfavorable childhood Hodgkin’s disease with VEPA and low-dose, involved-field radiation // J. Clin. Oncol. – 2002. – Vol. 20. – No. 14. – P. 3088-3094. 20. Fryer C.J., Hutchinson R.J., Krailo M. et al. Efficacy ant toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin’s disease in children: a report from the Children’s Cancer Study Group // J. Clin. Oncol. – 1990. – Vol. 8. – No. 12. – P. 1971-1980. 21. Fuller L.M., Gamble Y.F., Velasquez W.G. et al. Evaluation of the significance of prognostic factors in stage III Hodgkin’s disease treated with MOPP and radiotherapy // Cancer. – 1980. – Vol. 45. – P. 1352-1364. 22. Gobbi P.G., Broglia C., Berte R. et al. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin’s disase // Haematologica. – 2000. – Vol. 85. – No. 7. – P. 722-728. 23. Gobbi P.G., Broglia C., Levis A. et al., MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin’s lymphoma: 10-year results, late toxicity and second tumors // Clin. Cancar. Res. – 2006. – Vol. 12. – No. 2. – P. 529-535. 24. Gobbi P., Levis A., Chisesi T. et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linformi // J. Clin. Oncol. – 2005. – Vol. 23. – No. 36. – P. 9198-9207. 25. Hodgkin Th. On some morbid appearences of the absorbent glands and spleen // Med. Chir. Trans. – 1832. – Vol. 17. – P. 68-114. 26. Hoppe R.T. The contemporary management of Hodgkin’s disease // Radiology. – 1988. – Vol. 169. – P. 297-304. 27. Hoppe R.T., Coleman C.N., Cox P.S. et al. The management of stage I-II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience // Blood. – 1982. – Vol. 59. – P. 455-465. 28. Hoppe R.T., Rosenberg S.A., Kaplan H.S. et al. Prognostic factors in pathological stage IIIA Hodgkin’s disease // Cancer. – 1980. – Vol. 46. – P. 1240-1246. 29. Hudson M.M., Greenwald C., Thompson E. et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin’s disease // J. Clin. Oncol. – 1993. – Vol. 11. – No. 1. – P. 100-108. 30. Hudson M.M., Krasin M., Link M.P. et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin’s disease // J. Clin. Oncol. – 2004. – Vol. 22. – No. 22. – P. 4541-4550. 31. Hunger S.P., Link M.P., Donaldson S.S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin’s disease: the Stanford experience // J. Clin. Oncol. – 1994. – Vol. 12. – No. 10. – P. 2160-2166. 32. Hutchinson R.J., Fryer C.J., Davis P.C. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin’s disease in children: results of the Children’s Cancer Group. Phase III trial // J. Clin. Oncol. –1998. – Vol. 16. – P. 897-906. 33. Jenkin D., Doyle J., Berry M. et al. Hodgkin’s disease in children: treatment with MOPP and low-dose, extended field irradiation without laparotomy: late results and toxicity // Med. Ped. Oncol. – 1990. – Vol. 18. – P. 265-272. 34. Johnson P.W., Radford J.A., Cullen M.H. et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519) // J. Clin. Oncol. – 2005. – Vol. 23. – P. 9208-9218. 35. Landman-Parker J., Pacquement H., Leblanc T. et al. Localized childhood Hodgkin’s disease: response-adapted chemotherapy with Etoposide, Bleomycin, Vinblastine, and Prednisone before low-dose radiation therapy – results of the French Society of Pediatric Oncology Study MDH90.//J.Clin.Oncol.- 2000. – Vol. 18. – No. 7.- P.1500-1507. 36. Leiw K.H. Ding J.C., Cruickshank D. et al. Prognostic factors in patients with subdiaphragmatic Hodgkin’s disease // Hematol. Oncol. – 1983. – Vol. 1. – P. 205-214. 37. Lobo-Sanahuya F., Garsia I., Barrantes J. Pediatric Hodgkin’s disease in Costa Rica: twelve years’ experience of primary treatment by chemotherapy alone, without laparotomy // Med. Pediatr. Oncol. – 1994. – Vol. 22. – P. 398-403. 38. Mauch P., Goodman R., Rosenthal D.S. et al. An evaluation of total nodal irradiation as treatment for stage IIIA Hodgkin’s disease // Cancer. – 1979. – Vol. 43. – P. 1255-1261. 39. Minot G.R. and Isaacs R. Lymphoblastoma (malignant lymphoma); age and sex incidence, duration of disease, and the effects of roentgen-ray and radium irradiation and surgery // J. A. M. A. – 1926. – Vol. 86. – P. 1185-1189. 40. Mintz U., Miller J.B., Golomb H.M. et al. Pathologic stage I and II Hodgkin’s disease // Cancer. – 1979. – Vol. 44. – P.1101. 41. Nachman J.B., Sposto R., Herzog P. et al. Randomized comparison of low-dose involvedfield radiotherapy and no radiotherapy for children with Hodgkin's disease who achieved a complete response to chemotherapy. // J. Clin. Oncol. - 2002. - Vol. 20. - ¹ 18. - P. 3765- 3771. 42. Nissen N.I., Nordentoft A.M. Radiotherapy versus combined modality treatment of stage I and II Hodgkin’s disease // Cancer/ Treatm. Repts. – 1982. – Vol. 66. – P. 799-803. 43. Oberlin O., Lewerger G., Paquement H. et. al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease. The experience of the French Society of Pediatric Oncology // J. Clin. Oncol. – 1992. – Vol. 10. – No. 10. – P. 1602 – 1608. 44. Pusey W.A. Cases of sarcoma and of Hodgkin’s disease treated by exposures to X-rays: a preliminary report // JAMA. – 1902. – Vol. 38. – P. 166-169. 45. Reed D.M. On the pathological changes in Hodgkin’s disease, with especial reference to its relation to tuberculosis // Johns Hopkins Hosp. Rep. – 1902. – Vol. 10. – P. 133-196. 46. Rodgers R.W., Fuller L.M., Hagemeister F.B. et al. Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin’s disease treated with MOPP and radiotherapy // Cancer. – 1981. – Vol. 47. – P. 2196-2203. 47. Sackmann-Muriel F., Zubizarreta P., Gallo G. et al. Hodgkin’s disease in children: results of a prospective randomized trial in a single institute in Argentina // Med. Pediatr. Oncol. – 1997. – Vol. 29. – P. 544-552. 48. Schellong G. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. // Ann. Oncol. - 1996. - Vol. 7. - ¹ 4. - P. 67-72. 49. Schellong G., Brämswig J.H., Hörnig-Franz I. Treatment of children with Hodgkin's disease - results of the German Pediatric Oncology Group. // Ann. Oncol. - 1992. - Vol. 3. - ¹ 4. - P. 73-76. 50. Schellong G., Brämswing J., Hörning-Franz I. Hodgkin’s disease in children: combined modality treatment for stages IA, IB and IIA // Ann. Oncol. – 1994. – Vol. 5 (Suppl. 2). – P. 113-115. 51. Schellong G., Hornig-Franz I., Riepenhausen M. et al. Hodgkin’s disease Stage IV Study (SIOP-HD-IV/87) // SIOP News. – 1993. – No. 7. – P. 5. 52. Shankar A.G., Ashley S., Atra A. et al. A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin’s disease // Eur. J. Cancer. – 1998. – Vol. 34. – No. 13. – P. 2058-2063. 53. Shankar A.G., Ashley S., Radford N. et al. Does histology influence outcome in childhood Hodgkin’s disease? Results from the United Kingdom Children’s Cancer Study Group // J. Clin. Oncol. – 1997. – Vol. 15. – No. 7. – P. 2622-2630. 54. Shimkin M.B., Opperman K.C., Bostick W.L. and Low-Beer B.V.A. Hodgkin’s disease: an analysis of frequency distribution and mortality at the University of California Hospital, 1914-1951 // Ann. Int. Med. – 1955. – Vol. 42. – P. 136-153. 55. Slaughter D.P. and Craver L.F. Hodgkin’s disease; 5 year survival rate; value of early surgical treatment; notes on 4 cases of long duration // Am. J. Roentgenol. – 1942. – Vol. 47. – P. 596-606. 56. Sripada S.S., Tenali S.G., Vasudevan M., Viswanadhan S. Hybrid (COPP/ABV) therapy in childhood Hodgkin’s disease: a study of 53 cases during 1989-1993 at the Cancer Institute, Madras // Pediatr. Hemanol. Oncol. – 1995. – Vol. 12. – P. 333-341. 57. Sternberg C. Uber eine eigenartige unter dem bilde der pseudoleukemie verlaufende tuberkulose des lymphatischen apparates // Z. Heilk. – 1898. – Bd. 19. – S. 21-90. 58. Teillet F., Delbrück H., Bayle-Weisgerber Ch. Et al. Möglichkeiten einer therapiereduction beim morbus Hodgkin. II. Ermöglicht eine primäre polychemotherapie der verzicht auf eine exlorative splenektomie bei klinisch lokalisiertem krankheitsbefall? // Dtsch. Med. Wochenschr. – 1979. – Bd. 104. – S. 1405-1409. 59. Van den Berg H., Stuve W., Behrendt H. Treatment of Hodgkin’s disease in children with alternating mechlorethemine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy // Med. Pediatr. Oncol. – 1997. – Vol. 29. – P. 23-27. 60. Weiner M.A., Leventhal B., Brecher M.L. et al. Randomized study of intensive MOPPABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group Study // J. Clin. Oncol. – 1997. – Vol. 15. – No. 8. – P. 2769-2779. 61. Wiernik P.H., Gustafson J., Schimpff S.C. et al. Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Results eight years later // Am. J. Med. – 1979. – Vol. 67. – P. 183-193. | ||
| |||
Ôåäåðàëüíîå ãîñóäàðñòâåííîå áþäæåòíîå ó÷ðåæäåíèå íàóêè